Zobrazeno 1 - 10 of 16 pro vyhledávání: '"Ilian, Tchakov"'
3
Akademický článek
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers
Autor: Aurélien Marabelle, Aung Naing, Funda Meric-Bernstam, Xingfeng Bao, Andrea Varga, David S Hong, Aparna Parikh, Geoffrey I Shapiro, Özlem Ataman, Larisa Reyderman, Terri A Binder, Min Ren, Mingjie Liu, Satish Dayal, Amy Y Siu, Pallavi Sachdev, Lucy Xu, Vijay Bhagawati-Prasad, Ilian Tchakov, Chean Eng Ooi
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background E7046 is a highly selective, small-molecule antagonist of the E-type prostanoid receptor 4 (EP4) for prostaglandin E2, an immunosuppressive mediator of the tumor immune microenvironment. This first-in-human phase 1 study assessed the safet
Externí odkaz: https://doaj.org/article/e224332c09c046d89e9e666fa3f6b4e3
Zobrazit plný text záznamu
5
515 A phase 1 study of myeloid modulating agent MTL-CEBPA in combination with pembrolizumab in adult patients with advanced solid tumours
Autor: Nagy A. Habib, Nina Raulf, Ilian Tchakov, Ruth Plummer, Debashis Sarker, Laura Sinigaglia, Robert Habib, Mikael H. Sodergren, Alessio Cortellini, Thomas Talbot, Vikash Reebye, Antonio D'Alessio, John J. Rossi, David J. Pinato, Duncan Spalding
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundMTL-CEBPA is a novel immunotherapy targeting the myeloid cell lineage which has shown promising clinical activity as monotherapy and combination therapy with tyrosine kinase inhibitors in hepatocellular carcinoma (HCC). Immunosuppressive my
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca78229cbaf3715855bb138df71d87da
https://doaj.org/article/fdc64506c84049fba3af5bccffee47ef
Zobrazit plný text záznamu
6
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)
Autor: Maja J.A. de Jonge, Jan H.M. Schellens, Diane A.J. van der Biessen, Andre T. Brunetto, Agnes Jager, Johann S. de Bono, Joo Ern Ang, Martijn P. Lolkema, Jacques De Greve, Hendrik-Tobias Arkenau, Ruud van der Noll, Ilian Tchakov, Jos H. Beijnen, Marja Mergui-Roelvink, Serena Marchetti
Publikováno v: Investigational New Drugs, 38(4), 1096-1107. Kluwer Academic
Investigational New Drugs, 38. Kluwer Academic Publishers
Background In the first part of this extensive phase I study (NCT00516724), continuous olaparib twice daily (bid) with carboplatin and/or paclitaxel resulted in myelosuppression and dose modifications. Here, we report the safety, tolerability, and ef
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::082dde6f0d16999d82d6405628aff352
https://doi.org/10.1007/s10637-019-00857-6
Zobrazit plný text záznamu
7
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE
Autor: David S, Hong, Aparna, Parikh, Geoffrey I, Shapiro, Andrea, Varga, Aung, Naing, Funda, Meric-Bernstam, Özlem, Ataman, Larisa, Reyderman, Terri A, Binder, Min, Ren, Mingjie, Liu, Satish, Dayal, Amy Y, Siu, Pallavi, Sachdev, Lucy, Xu, Vijay, Bhagawati-Prasad, Ilian, Tchakov, Chean Eng, Ooi, Xingfeng, Bao, Aurelien, Marabelle
Publikováno v: Journal for Immunotherapy of Cancer
Background E7046 is a highly selective, small-molecule antagonist of the E-type prostanoid receptor 4 (EP4) for prostaglandin E2, an immunosuppressive mediator of the tumor immune microenvironment. This first-in-human phase 1 study assessed the safet
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::145fdac8f1ef2ea42f708c1157066faa
https://pubmed.ncbi.nlm.nih.gov/32554609
Zobrazit plný text záznamu
8
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers
Autor: Pallavi Sachdev, Amy Siu, Xingfeng Bao, Geoffrey I. Shapiro, Aung Naing, Vijay Bhagawati-Prasad, O. Ataman, Aurélien Marabelle, Lucy Xu, David S. Hong, Larisa Reyderman, Terri A. Binder, Satish Dayal, Andrea Varga, Aparna Raj Parikh, Mingjie Liu, Funda Meric-Bernstam, Ilian Tchakov, Min Ren, Chean Eng Ooi
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundE7046 is a highly selective, small-molecule antagonist of the E-type prostanoid receptor 4 (EP4) for prostaglandin E2, an immunosuppressive mediator of the tumor immune microenvironment. This first-in-human phase 1 study assessed the safety
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a926ef25c1c8bbba411f7030246ddd5b
https://doi.org/10.1136/jitc-2019-000222
Zobrazit plný text záznamu
10
Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study
Autor: Stanislaw Korzeniowski, Madeleine A. Kane, Ilian Tchakov, Vincent Grégoire, David Raben, Andrzej Kawecki, Pramod Kumar Julka, Srihari Prasad, Marc Hamoir, Hung-Ming Wang, Anil K. D'Cruz, R. Kumar, Jean-Pascal Machiels, Mark V. Sellers, Jacek Fijuth, Ljiljana Radosevic-Jelic, Changhu Chen
Publikováno v: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 100(1)
BACKGROUND AND PURPOSE: To assess the efficacy and safety of gefitinib given concomitantly and/or as maintenance therapy to standard cisplatin/radiotherapy for previously untreated, unresected, stage III/IV non-metastatic SCCHN. MATERIALS AND METHODS
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e21d82ac1d688d81a6a8109847423d73
https://pubmed.ncbi.nlm.nih.gov/21821303
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje